Designation supported by robust clinical data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of ...

Relay Therapeutics upgraded to Outperform: zovegalisib PI3Kα breast cancer catalyst, $596M cash to 2029, Phase 3 mid-2026. Click for more on RLAY stock.

Relay Therapeutics gets US FDA Breakthrough Therapy Designation for zovegalisib to treat advanced breast cancer: Cambridge, Massachusetts Thursday, February 5, 2026, 16:00 Hrs [IS ...

The BTD for zovegalisib is supported by data from the Phase I/II ReDiscover trial.

Investing.com -- Relay Therapeutics Inc (NASDAQ:RLAY) stock rose 5.8% in premarket trading Monday after Oppenheimer upgraded the biotech company from Perform to Outperform with a price target of ...

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Relay Therapeutics, Inc. is the next best ...

The 55 meters shapes up as the must‑watch event in North 2, Group 3, with a potential photo finish on the horizon. Middletown ...

AI coding is big right now, and LinkedIn has given employers a way to track down workers with the exact skills they need. The ...

Relay Therapeutics shares were 9% higher, at $8.85, after the company said the Food and Drug Administration has granted Breakthrough Therapy Designation to zovegalisib in combination with fulvestrant ...

NBA rumors reveal the San Antonio Spurs’ stance on a potential Giannis Antetokounmpo trade with the Milwaukee Bucks as the deadline nears.

Kirsty Coventry, elected last March as the first female president of the International Olympic Committee, touts the Milan ...